See what’s driving market performance around the world in today’s Morning Lineup.  Bespoke’s Morning Lineup is the best way to start your trading day.  Read it now by starting a two-week free trial to Bespoke Premium.  CLICK HERE to learn more and start your free trial.

After trading lower overnight, US equity futures are modestly higher on the day as the market looks to escape a Corona Friday for the second week in a row.  You may recall that last Friday the S&P 500 closed out the week with a gain of 2.68%, which was the second-best Friday performance for the market all year.  For all of 2020, though, Fridays have been the worst day for the market with a median decline of 0.82% and gains barely even 25% of the time.

Be sure to check out today’s Morning Lineup for a rundown of the latest earnings reports, sentiment data in Germany, and the latest data on the coronavirus outbreak.


Yesterday wasn’t a great day for the biotech sector as reports that Gilead’s COVID-19 treatment remdesivir didn’t perform well in a small trial of Chinese patients.  While details surrounding the data were scant, the news caused an 11.4% intraday negative reversal in GILD’s stock and also reversed what was a pretty strong market rally.  GILD has over a 9% weighting in the VanEck Biotech ETF (BBH), so its reversal had an impact on that ETF as well.  However, after a remarkable 31% off the March lows, which erased all of the late February/March declines, BBH still remains above its breakout point in the low $140s.

Print Friendly, PDF & Email